

## Fate Therapeutics to Present at Two Upcoming Conferences in March

SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will present at two conferences in March. The presentations will feature a business overview and a scientific update.

- | Scott Wolchko, Fate's President and Chief Executive Officer, will present a Company overview at the **29<sup>th</sup> Annual ROTH Conference** at 2:30 p.m. PT on Monday, March 13, 2017 in Orange County, CA.
- | Bob Valamehr, Ph.D., Fate's VP Cancer Immunotherapy Research, will present a Company scientific update entitled "Using Engineered Pluripotent Cells as a Renewable Source for Off-the-Shelf Cancer Immunotherapy" at the **World ADOPT Summit 2017** at 2:30 p.m. GMT on Thursday, March 9, 2017 in London, England.

A live webcast of the 29<sup>th</sup> Annual ROTH Conference presentation will be available through the investor relations section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). Following the live webcast, an archived replay of the presentation will be available on the Company's website for 30 days after the conference.

### About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel *ex vivo* cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

#### Contact:

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina@sternir.com](mailto:christina@sternir.com)